SECTORS · HEALTHCARE
Healthcare
Drug makers, biotech, medical device and research companies. New drugs, regulation and clinical results drive their earnings.
Stocks in this sector
By overall scoreKorea 16 stocks
| Rank | Grade | Stock | Overall score | Change % |
|---|---|---|---|---|
| 1 | A | PharmaResearch Co., Ltd. | 84 | -3.14% |
| 2 | A | Hugel, Inc. | 73 | -2.55% |
| 3 | A | Alteogen Inc. | 72 | -5.12% |
| 4 | B | SK biopharmaceuticals Co., Ltd. | 69 | -1.71% |
| 5 | B | Hanmi Pharm. Co., Ltd. | 69 | -7.42% |
| 6 | B | SAMSUNG BIOLOGICS CO.,LTD. | 67 | +3.13% |
| 7 | B | Celltrion, Inc. | 65 | +0.61% |
| 8 | B | YUHAN CORPORATION | 65 | +3.16% |
| 9 | B | Peptron, Inc. | 54 | -1.68% |
| 10 | B | SAM CHUN DANG PHARM CO. LTD | 53 | -7.33% |
| 11 | C | SK Bioscience Co.,Ltd | 46 | -3.17% |
| 12 | C | LigaChem Biosciences Inc. | 45 | -4.24% |
| 13 | C | HANALL BIOPHARMA CO.,LTD | 42 | -3.22% |
| 14 | C | ABL Bio Inc. | 39 | -6.38% |
| 15 | C | Voronoi, Inc. | 38 | -3.81% |
| 16 | C | HLB Co.,LTD. | 32 | -3.93% |
US 24 stocks
| Rank | Grade | Stock | Overall score | Change % |
|---|---|---|---|---|
| 1 | A | Stryker Corporation | 82 | -0.33% |
| 2 | A | Agilent Technologies, Inc. | 80 | +1.40% |
| 3 | A | Regeneron Pharmaceuticals, Inc. | 77 | +3.35% |
| 4 | A | Johnson & Johnson | 76 | +2.13% |
| 5 | A | Medtronic plc | 76 | +1.31% |
| 6 | A | Vertex Pharmaceuticals Incorporated | 74 | +2.74% |
| 7 | A | Danaher Corporation | 73 | +0.83% |
| 8 | A | Bristol-Myers Squibb Company | 73 | +4.61% |
| 9 | A | Eli Lilly and Company | 71 | +3.62% |
| 10 | A | Abbott Laboratories | 70 | +0.35% |
| 11 | A | Edwards Lifesciences Corporation | 70 | +1.38% |
| 12 | B | Thermo Fisher Scientific Inc. | 67 | +1.53% |
| 13 | B | Amgen Inc. | 65 | +3.21% |
| 14 | B | Pfizer Inc. | 64 | +2.96% |
| 15 | B | IDEXX Laboratories, Inc. | 64 | +1.67% |
| 16 | B | Intuitive Surgical, Inc. | 62 | -0.43% |
| 17 | B | The Cigna Group | 62 | +2.50% |
| 18 | B | Elevance Health, Inc. | 61 | +0.66% |
| 19 | B | Gilead Sciences, Inc. | 60 | +3.80% |
| 20 | B | Boston Scientific Corporation | 60 | -0.72% |
| 21 | B | AbbVie Inc. | 59 | +3.32% |
| 22 | B | UnitedHealth Group Incorporated | 55 | +4.73% |
| 23 | B | HCA Healthcare, Inc. | 54 | +2.10% |
| 24 | B | McKesson Corporation | 50 | +1.53% |
Sector metric profile
Medians of the 40 stocks in Healthcare, placed next to the medians of the other sectors on Jupick. The left end of each track is the sector with the lowest median and the right end the highest. The vertical line marks the median of all listed stocks.
- PER29.0x · 33 stocks
- PBR4.7x · 37 stocks
- ROE13.5% · 37 stocks
- Operating margin24.2% · 40 stocks
- Debt ratio54.9% · 36 stocks
- Dividend yield0.7% · 30 stocks
The position only orders values by size. A larger value is not better or worse for any metric. Each sector has its own baseline: capital-heavy sectors tend to show higher debt ratios, and sectors with high growth expectations tend to show higher PER. Stocks whose PER or PBR is not meaningful because of losses, and stocks whose financials have not arrived yet, are left out. Metrics with fewer than 5 valid stocks are not shown.
Korea and US medians
Metric medians counted separately for 16 Korean and 24 US stocks in Healthcare. Only ratio metrics that compare across currencies are used, and only metrics with at least 5 valid stocks on both sides are shown.
| Metric | Korea | US |
|---|---|---|
| PER | 29.2x 9 in sample | 28.9x 24 in sample |
| PBR | 7.0x 16 in sample | 4.7x 21 in sample |
| ROE | 4.6% 16 in sample | 15.8% 21 in sample |
| Operating margin | 4.2% 16 in sample | 27.4% 24 in sample |
| Debt ratio | 45.0% 16 in sample | 66.2% 20 in sample |
| Dividend yield | 0.5% 6 in sample | 1.0% 24 in sample |
Of 6 metrics compared, the Korean median is lower than the US median for 4 and higher for 2.
Even within one sector, Korea and the US differ in the mix and size of listed companies, accounting rules and dividend habits, so the numbers can be far apart. A larger value on either side is not better or worse. Stocks whose PER or PBR is not meaningful because of losses, and stocks whose financials have not arrived yet, are left out, so sample sizes differ by metric.
Sector classification is based on public data and is for information only. Grades and price moves summarize the current state and are not investment advice or a forecast.